Skip to Content

Dacarbazine meda powder for solution for injection infusion – Change to required period of contraception for female patients

29/02/2024
Medicines for human use Product information update (PIU)

This update is to inform healthcare professionals of a recent update to the product information for Dacarbazine medac, powder for solution for injection/infusion. This update relates to the required period of contraception for female patients of reproductive potential.

Please see the document linked below for further information.

Product name or type:

  • Dacarbazine medac 200 mg, powder for solution for injection/infusion (PA0623/003/002)
  • Dacarbazine medac 500 mg, powder for solution for injection/infusion (PA0623/003/003)
  • Dacarbazine medac 1000 mg, powder for solution for injection/infusion (PA0623/003/004)

Product information

Active substance
Dacarbazine
Authorisation holder
Medac
Authorisation number

PA0623/003/002-004

 

Human or veterinary medicine
Human Medicine

Documents

Opens in new window Dacarbazine meda powder for solution for injection infusion Product Information Update 29 February 2024 PDF : 148KB | 01/11/2024